TY - JOUR
T1 - Clinical outcome in patients with intramedullary spinal cord metastases from lung cancer
AU - Conill, C.
AU - Marruecos, J.
AU - Verger, E.
AU - Berenguer, J.
AU - Lomeña, F.
AU - Domingo-Domènech, J.
AU - Grau, J. J.
AU - Casas, F.
PY - 2007
Y1 - 2007
N2 - Intramedullary spinal cord metastases (ISCM) are uncommon and present with rapidly progressing neurological deficits. The objective of this study was to determine the rate, duration of neurological response and survival after radiation therapy. We have retrospectively reviewed the clinical outcome of six cases with a diagnosis of ISCM from primary lung cancer, non-small cell (NSCLC) (n = 3) and small cell (SCLC) (n = 3). Total radiation dose ranged from 27 Gy/5 fr to 40 Gy/20 fr. Ambulation was preserved in 3 patients and partially recovered in one. Five out of the six patients (83%) showed improvement in neurological signs/symptoms with a mean duration of 17.2 days (max: 40 days; min: 6 days). Median survival time was 5 months (confidence interval (CI) 95%: 0-12) for NSCLC and 5 months (CI 95%: 4-6) for SCLC. Although radiation response rate is high, the interval free of neurological progression is very short. A therapeutic approach should be considered for each individual.
AB - Intramedullary spinal cord metastases (ISCM) are uncommon and present with rapidly progressing neurological deficits. The objective of this study was to determine the rate, duration of neurological response and survival after radiation therapy. We have retrospectively reviewed the clinical outcome of six cases with a diagnosis of ISCM from primary lung cancer, non-small cell (NSCLC) (n = 3) and small cell (SCLC) (n = 3). Total radiation dose ranged from 27 Gy/5 fr to 40 Gy/20 fr. Ambulation was preserved in 3 patients and partially recovered in one. Five out of the six patients (83%) showed improvement in neurological signs/symptoms with a mean duration of 17.2 days (max: 40 days; min: 6 days). Median survival time was 5 months (confidence interval (CI) 95%: 0-12) for NSCLC and 5 months (CI 95%: 4-6) for SCLC. Although radiation response rate is high, the interval free of neurological progression is very short. A therapeutic approach should be considered for each individual.
KW - Intramedullary spinal cord metastases
KW - Lung cancer
KW - Magnetic resonance imaging
KW - Positron emission tomography
KW - Radio therapy
UR - http://www.scopus.com/inward/record.url?scp=34250354490&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34250354490&partnerID=8YFLogxK
U2 - 10.1007/s12094-007-0031-6
DO - 10.1007/s12094-007-0031-6
M3 - Article
C2 - 17403628
AN - SCOPUS:34250354490
SN - 1699-048X
VL - 9
SP - 172
EP - 176
JO - Clinical and Translational Oncology
JF - Clinical and Translational Oncology
IS - 3
ER -